ABCSG 63 / ERIKA Overview
Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer
An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer
| Studienstart: | Q3/2025 |
| Coordinating Investigators: | Christian Singer, Vienna Michael Gnant, Vienna |
| Participants: | 120 (Austria, Germany) |
| Study Design (Click to enlarge) |
 |
Share on